Clinical trials: Resectable Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
The goal of this clinical trial is to evaluate the clinical value of ctDNA testing in guiding the optimization of immunochemotherapy cycles during induction treatment for resectable patients with NSCLC.
- Trial name
- PROPHET (NCT06977074)
- Testing
- PD-1 inhibitor, Platinum Doublet
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Sun Yat-sen University
Non Small Cell Lung Cancer
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
This is a clinical study on the efficacy and safety of TQB2450 injection combined with chemotherapy or anlotinib hydrochloride capsule in the perioperative treatment of resectable non-small cell lung cancer.
- Trial name
- NCT05913089
- Testing
- TQB2450 injection + Chemotherapy, TQB2450 injection + Anlotinib Hydrochloride Capsule
- Where
- 10 sites in China
- Volunteers
- 58 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Lung Cancer
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
This is a phase I dose escalation study of CAN-2409 plus prodrug in patients with non-small cell lung cancer (NSCLC). The primary clinical objective of the study is to evaluate the safety of CAN-2409 plus prodrug when combined…
- Trial name
- NCT03131037
- Testing
- CAN-2409 + valacyclovir
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Candel Therapeutics, Inc.
Non Small Cell Lung Cancer
This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response
A total of 58 patients were enrolled in this exploratory study and randomly assigned to cohort 1 and cohort 2, with 29 patients in each group.
- Trial name
- NCT06851169
- Testing
- Cohort 1: Neoadjuvant therapy (benmelstobart combined with anlotinib), Cohort 2: Neoadjuvant therapy (benmelstobart only)
- Volunteers
- 58 people
- Sponsor
- Tang-Du Hospital
Non-small Cell Lung Cancer (NSCLC)
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined with osimertinib in the study population and to…
- Trial name
- NCT03255083
- Testing
- DS-1205c, Osimertinib
- Where
- 7 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- Daiichi Sankyo
Stage III Non-small Cell Lung Cancer
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
For stage III non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients could not achieve complete pathological response (CPR).
- Trial name
- NCT05891080
- Testing
- Toripalimab, JS004, Pemetrexed
- Volunteers
- 124 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
NSCLC
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
This is an open-label, randomized, single-center study. This translational study aims to explore tumor microenvironment remodelling after induction therapy lorlatinib and identify mechanisms of disease persistence and potential…
- Trial name
- NCT06893354
- Testing
- lorlatinib, lorlatinib plus chemotherapy
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Stage IIIA Non-Small Cell Lung Cancer
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
The purpose of this study is to determine the feasibility and evaluate the safety of delivering chemoradiotherapy, the usual approach to non-small cell lung cancer, in combination with pembrolizumab (MK-3745), followed by…
- Trial name
- NCT02987998
- Testing
- Cisplatin, Etoposide, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Nathan Pennell, MD, PhD
Non-Small Cell Lung Cancer
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy…
- Trial name
- AEGEAN (NCT03800134)
- Testing
- Durvalumab, Carboplatin, Cisplatin
- Where
- 231 sites in United States, Argentina and 26 more
- Volunteers
- 825 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who…
- Trial name
- NCT03217071
- Testing
- Pembrolizumab, stereotactic radiation therapy (SRT), Surgery (Non-interventional, standard of care)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sue Yom
Lung Cancer, Non-small Cell Lung Cancer
Effects of Infusion Timing on Treatment Response in Solid Tumors
This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment…
- Conditions
- Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer
- Trial name
- TIMED (NCT07630168)
- Testing
- PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
NSCLC
Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer
Stratification of postoperative ctDNA status can effectively assess the risk of recurrence in patients. In addition, the multi-node dynamic monitoring of ctDNA is more effective in predicting the recurrence risk of patients.
- Trial name
- MRDinS3LC (NCT06081777)
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking University Cancer Hospital & Institute
Non-small Cell Lung Cancer
Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients
The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer
- Trial name
- NCT03613467
- Testing
- VATS lobectomy, Thoracotomy lobectomy
- Where
- 10 sites in China
- Volunteers
- 2,145 people
- Sponsor
- Tang-Du Hospital
Non-small Cell Lung Cancer
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
AK104, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy.
- Trial name
- NCT05377658
- Testing
- AK104, Albumin-Bound Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Henan Cancer Hospital
Carcinoma, Non-Small-Cell Lung (NSCLC)
Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung Cancer
Neoadjuvant chemoimmunotherapy has improved outcomes in patients with resectable non-small cell lung cancer (NSCLC), but a substantial proportion of patients do not achieve a major pathological response.
- Trial name
- NEOCTATC (NCT07855965)
- Testing
- Cryo-Thermal Ablation, Toripalimab, Platinum-based doublet chemotherapy
- Where
- 9 sites in China
- Volunteers
- 40 people
- Sponsor
- West China Hospital
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy…
- Trial name
- NCT03574649
- Testing
- Nab-paclitaxel, Cisplatin, 5Fluorouracil
- Where
- United States
- Sponsor
- ImmunityBio, Inc.
Non-Small Cell Lung Cancer
A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
This is a Phase II, open-labeled, single-arm, study of neoadjuvant BL-B01D1in combination with Almonertinib followed by adjuvant Almonertinib for the treatment of Patients with EGFR-Mutation Positive Stage II-IIIB Resectable…
- Trial name
- NCT06951464
- Testing
- BL-B01D1, Almonertinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Non Small Cell Lung Cancer
Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer
This is an open-label, single-arm, phase II, multi-center clinical trial. Thirty patients will be enrolled in this trial to investigate the pathological complete response rate defined as the absence of residual tumor in lung and…
- Trial name
- NeoTAP01 (NCT04304248)
- Testing
- Albumin-bound paclitaxel, Carboplatin, Toripalimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hao Long
NSCLC Stage II, NSCLC Stage III
Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in…
- Trial name
- NCT07410975
- Testing
- sintilimab+IBI310+chemotherapy
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China